Evidence map›Paper›PMID 34772791›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022

Glypican-3-Targeted

Kevin P Labadie, Donald K Hamlin, Aimee Kenoyer, Sara K Daniel, Alan F Utria, Andrew D Ludwig, Heidi L Kenerson, Lily Li, Jonathan G Sham, Delphine L Chen and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Tetraspanin-8 as a Tumor-Selective Immuno-PET Target in Hepatocellular Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  6. Article
  7. CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  8. Review
  9. Article
  10. Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Evaluation of Candidate Theranostics forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Kevin P LabadieDepartment of Surgery, University of Washington, Seattle, Washington.
Donald K HamlinDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
Aimee KenoyerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Sara K DanielDepartment of Surgery, University of Washington, Seattle, Washington.
Alan F UtriaDepartment of Surgery, University of Washington, Seattle, Washington.
Andrew D LudwigDepartment of Surgery, University of Washington, Seattle, Washington.
Heidi L KenersonDepartment of Surgery, University of Washington, Seattle, Washington.
Lily LiLife Sciences Division, TRIUMF, and Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada.
Jonathan G ShamDepartment of Surgery, University of Washington, Seattle, Washington.
Delphine L ChenDepartment of Radiology, University of Washington, Seattle, Washington.
Johnnie J OrozcoClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Raymond S YeungDepartment of Surgery, University of Washington, Seattle, Washington.
Chris OrvigMedicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada.
Yawen LiDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
D Scott WilburDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
James O ParkDepartment of Surgery, University of Washington, Seattle, Washington; jopark@uw.edu.
University of Washington · USCancer Research Center · USTRIUMF · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality worldwide, with limited therapeutic options for advanced disease. Targeted α-therapy is an emerging class of targeted cancer therapy in which α-particle-emitting radionuclides, such as

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsCell Line, TumorGlypicansHumansMiceTissue DistributionTumor BurdenXenograft Model Antitumor AssaysGlypicansGPC3 protein, humanglypican-3 (GPC3)hepatocellular carcinoma (HCC)radioimmunotherapytargeted α-therapy (TAT)

Identifiers

PMID34772791
PMCPMC9258570
OpenAlexW3214077599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.